Preliminary data from Phase 2 trials of opaganib from Israel’s Redhill (reported here previously) on 40 hospitalized Covid-19 patients showed positive results. Patients receiving opaganib had significantly reduced dependence on ventilators and faster time to discharge.

https://www.prnewswire.com/il/news-releases/redhill-s-phase-2-3-covid-19-candidate-opaganib-reduces-ards-related-blood-clotting-in-preclinical-model-813822864.html